Cellular and molecular characterization of the scurfy mouse mutant.
暂无分享,去创建一个
S. Ziegler | F. Ramsdell | J. Wilkinson | L. Clark | M. Brunkow | M. Appleby | Clark Lb | J. Wilkinson | Clark Lb
[1] T. Sullivan,et al. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.
[2] J. Allison,et al. The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.
[3] J. Allison,et al. Co-stimulation in T cell responses. , 1997, Current opinion in immunology.
[4] A. Weiss,et al. T cell antigen receptor signal transduction. , 1997, Current opinion in cell biology.
[5] J. Allison,et al. T cell-mediated elimination of B7.2 transgenic B cells. , 1997, Immunity.
[6] G. Freeman,et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. , 1997, Journal of immunology.
[7] J. Wang,et al. IL-2 and IL-4 mediate through two distinct kinase pathways for the activation of alphaCD3-induced activated killer cells. , 1996, Cellular immunology.
[8] L Timmermann,et al. The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.
[9] M. Lovett,et al. Identification of the homologous beige and Chediak–Higashi syndrome genes , 1996, Nature.
[10] J. Bluestone,et al. CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.
[11] V. Godfrey,et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes , 1996, European journal of immunology.
[12] D. Hafler,et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.
[13] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[14] U. Francke,et al. The mouse homolog of the Wiskott-Aldrich syndrome protein (WASP) gene is highly conserved and maps near the scurfy (sf) mutation on the X chromosome. , 1995, Genomics.
[15] J. Bluestone,et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.
[16] H. Weiner,et al. Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation , 1995, European journal of immunology.
[17] K. Siminovitch,et al. Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: a step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function. , 1994, Clinical immunology and immunopathology.
[18] V. Godfrey,et al. CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. , 1994, Journal of immunology.
[19] P. Linsley,et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.
[20] P. Linsley,et al. CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.
[21] V. Godfrey,et al. Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. , 1994, The American journal of pathology.
[22] G. Freeman,et al. A negative regulatory function of B7 revealed in B7-1 transgenic mice. , 1994, Immunity.
[23] D J Rawlings,et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.
[24] W. Paul,et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. , 1993, Science.
[25] C. June,et al. The protein tyrosine kinase inhibitor herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. , 1992, International immunology.
[26] P. Linsley,et al. CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.
[27] V. Godfrey,et al. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[28] K. Dorshkind. In vivo administration of recombinant granulocyte-macrophage colony-stimulating factor results in a reversible inhibition of primary B lymphopoiesis. , 1991, Journal of immunology.
[29] V. Godfrey,et al. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.
[30] J. Trevillyan,et al. Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. , 1990, Journal of immunology.
[31] M. Lyon,et al. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Gibbs,et al. The molecular basis of the sparse fur mouse mutation. , 1987, Science.
[33] N. Tanaka,et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. , 1996, Annual review of immunology.
[34] S. Schreiber,et al. The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.